Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- Check6 days agoChange DetectedSite revision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedThe revision history is updated to include v3.5.0 as the latest revision and removes v3.4.3.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page revision label was updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check71 days agoChange DetectedThe study status was updated to Completed with actual completion dates, replacing the previous 'Active, not recruiting' status. The page revision was updated to v3.4.2 and the funding-status notice was removed.SummaryDifference0.8%

- Check78 days agoChange DetectedA government funding status notice banner was added and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check85 days agoChange DetectedGlossary toggle added; a new label 'Last Update Submitted that Met QC Criteria' appears and a 'No FEAR Act Data' notice is shown. The site revision is updated from v3.3.4 to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.